Company

Insmed Incorporated

Headquarters: Bridgewater, NJ, United States

Employees: 613

CEO: Mr. William H. Lewis J.D., M.B.A.

NASDAQ: INSM -0.70%

Market Cap

$4.20 Billion

USD as of Jan. 1, 2024

Market Cap History

Insmed Incorporated market capitalization over time

Evolution of Insmed Incorporated market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Insmed Incorporated

Detailed Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Insmed Incorporated has the following listings and related stock indices.


Stock: NASDAQ: INSM wb_incandescent

Stock: FSX: IM8N wb_incandescent

Details

Headquarters:

700 US Highway 202/206

Bridgewater, NJ 08807-1704

United States

Phone: 908 977 9900